Pancreatic Disorders News

Serum albumin levels, specifically hypoalbuminemia, within 24 hours of hospital admission for acute pancreatitis may help predict adverse outcomes and mortality, according to researchers.

In the 36 months prior to diagnosis of pancreatic ductal adenocarcinoma, researchers observed “predominant changes” in patients’ body composition and biochemical markers, which may serve as potential biomarkers for early cancer detection.

Because the science underpinning medicine evolves so quickly, it is not uncommon for some doctors to manage patients based on old evidence that is no longer a best practice; this is called clinical inertia.

Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.

Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.

WASHINGTON — An algorithm that uses electronic health record parameters identified glycemic evidence of new-onset diabetes in real time, which could lead to earlier detection of pancreatic ductal adenocarcinoma, according to researchers.

Monthly olezarsen 80 mg significantly lowered triglyceride levels and also reduced incidence of acute pancreatitis vs. placebo in patients with familial chylomicronemia syndrome, according to a study in The New England Journal of Medicine.

A new ACG guideline published in The American Journal of Gastroenterology underscored that early management “is essential” to prevent complications such as organ failure and pancreatic necrosis in patients with acute pancreatitis.

The FDA has granted orphan drug designation to Ionis Pharmaceuticals’ olezarsen, an investigational ligand-conjugated antisense drug for the treatment of familial chylomicronemia syndrome, according to a company release.

Adults with type 2 diabetes who use GLP-1 receptor agonists do not have an increased short-term risk for pancreatic cancer, according to findings published in JAMA Network Open.